Lorenzo Falchi, MD, expands on efficacy results from arms 6 and 7 of the phase 1b/2 EPCORE NHL-2 trial of epcoritamab in first-line follicular lymphoma.
Exploring Bispecific Approaches in Frontline Non-Hodgkin Lymphoma
Epcoritamab-based treatment yielded durable remissions in patients with follicular lymphoma, both as first-line induction and maintenance.
Epcoritamab plus R-CHOP delivered durable remissions beyond 3 years across high-risk subgroups of patients with newly diagnosed DLBCL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5